Format

Send to

Choose Destination
See comment in PubMed Commons below
Toxicol In Vitro. 2006 Sep;20(6):923-35. Epub 2006 Mar 9.

Evaluation of DNA damage induced by atrazine and atrazine-based herbicide in human lymphocytes in vitro using a comet and DNA diffusion assay.

Author information

1
Institute for Medical Research and Occupational Health, Division for Mutagenesis, Ksaverska 2, 10000 Zagreb, Croatia. dzeljezi@imi.hr

Abstract

Atrazine is one of the most widely used herbicides in the world. When applied, it is not used as a pure active ingredient but in the form of commercial formulations. Besides atrazine, these formulations contain other substances that might represent a risk to human health due to their mutual interactions. We evaluated the genotoxicity, apoptosis and necrosis induction of atrazine as an active ingredient, the commercial formulation Gesaprim, and a Gesaprim adjuvant mixture without atrazine by comet and DNA diffusion assay, respectively. Human lymphocytes were treated for 0.5, 1, 3, 5, and 8 h with 0.047 microg/ml, 0.47 microg/ml, 4.7 microg/ml of substances tested both in the presence and in the absence of an exogenous metabolic activator. Atrazine did not appear to be genotoxic or to be capable of inducing apoptosis or necrosis. Unlike atrazine, Gesaprime and the adjuvant mixture increased DNA damage in lymphocytes. After 5 h of treatment, it also increased the number of apoptotic cells. Metabolic activation additionally enhanced the DNA-damaging potential of Gesaprim and the adjuvant mixture but did not affect atrazine genotoxicity. Thus, both assay endpoints differed significantly for the active ingredient and formulation. To evaluate the potential health risk of simultaneous exposure to adjuvants and an active ingredient, further efforts using a biomonitoring approach should be made.

PMID:
16527446
DOI:
10.1016/j.tiv.2006.01.017
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center